Long-term safety and tolerability of bimekizumab in patients with axial spondyloarthritis and psoriatic arthritis: Results from pooled phase 2b/3 studies

被引：0
|
作者：
Mease, P. J. [1 ,2 ]
Poddubnyy, D. [3 ]
Orbai, A. M. [4 ]
Warren, R. B. [5 ,6 ]
Fleurinck, C. [7 ]
Bajracharya, R. [8 ]
Ink, B. [8 ]
Massow, U. [9 ]
Shende, V [8 ]
Shepherd-Smith, J. [8 ]
Peterson, L. [10 ]
White, K. [8 ]
Landewe, R. [11 ]
Gensler, L. S. [12 ]
机构：
[1] Univ Washington, Swedish Med Ctr, Seattle, WA 98195 USA
[2] Univ Washington, Prov St Joseph Hlth, Seattle, WA 98195 USA
[3] Charite Univ Med Berlin, Dept Gastroenterol Infect Dis & Rheumatol, Berlin, Germany
[4] Johns Hopkins Univ, Sch Med, Div Rheumatol, Baltimore, MD USA
[5] Northern Care Alliance NHS Fdn Trust, Dermatol Ctr, Manchester, Lancs, England
[6] Univ Manchester, NHS Fdn Trust, NIHR Manchester Biomed Res Ctr, Manchester Acad Hlth Sci Ctr, Manchester, Lancs, England
[7] UCB Pharma, Brussels, Belgium
[8] UCB Pharma, Slough, Berks, England
[9] UCB Pharma, Monheim, Germany
[10] UCB Pharma, Morrisville, NY USA
[11] Amsterdam & Zuyderland MC, Amsterdam Rheumatol & Clin Immunol Ctr, Heerlen, Netherlands
[12] Univ Calif San Francisco, San Francisco, CA 94143 USA
来源：
SWISS MEDICAL WEEKLY | 2024年 / 154卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
IP 7
引用
收藏
页码：35S / 35S
页数：1
相关论文
共 50 条
  • [21] Bimekizumab Safety and Efficacy in Patients with Psoriatic Arthritis: 3-Year Results from a Phase 2b Open-Label Extension Study
    Coates, L. C.
    Warren, R. B.
    Ritchlin, C. T.
    Gossec, L.
    Merola, J. F.
    Assudani, D.
    Coarse, J.
    Eells, J.
    Ink, B.
    McInnes, I. B.
    SWISS MEDICAL WEEKLY, 2021, 151 : S20 - S20
  • [22] SUSTAINED IMPROVEMENT IN CLINICAL OUTCOMES AND LONG-TERM SAFETY OF BIMEKIZUMAB IN PATIENTS ACROSS THE SPECTRUM OF AXIAL SPONDYLOARTHRITIS UP TO WEEK 52: RESULTS FROM TWO PHASE 3 STUDIES
    Gaffney, Karl
    McKay, Neil D.
    Sengupta, Raj
    Fleurinck, Carmen
    de la Loge, Christine
    Massow, Ute
    Taieb, Vanessa
    Zhao, Sizheng Steven
    Marzo-Ortega, Helena
    RHEUMATOLOGY, 2024, 63
  • [23] Sustained improvement in clinical outcomes and long-term safety of bimekizumab in patients across the spectrum of axial spondyloarthritis up to week 52: results from two phase 3 studies
    Gaffney, Karl
    McKay, Neil D.
    Sengupta, Raj
    Fleurinck, Carmen
    de la Loge, Christine
    Massow, Ute
    Taieb, Vanessa
    Zhao, Sizheng Steven
    Marzo-Ortega, Helena
    RHEUMATOLOGY, 2024, 63
  • [24] Long-term safety and sustained efficacy of bimekizumab in patients with ankylosing spondylitis (radiographic axial spondyloarthritis): 5-year results from BE AGILE (phase 2b) and its open-label extension
    Deodhar, Atul
    Navarro-Compan, Victoria
    Poddubnyy, Denis
    Gensler, Lianne S.
    Ramiro, Sofia
    Tomita, Tetsuya
    Marzo-Ortega, Helena
    Fleurinck, Carmen
    Vaux, Thomas
    Massow, Ute
    de Peyrecave, Natasha
    van der Heijde, Desiree
    Baraliakos, Xenofon
    RMD OPEN, 2025, 11 (01):
  • [25] BIMEKIZUMAB EFFICACY AND SAFETY IN PATIENTS WITH PSORIATIC ARTHRITIS AND PSORIASIS: UP TO 2-YEAR RESULTS FROM TWO PHASE 3 STUDIES
    Thaci, Diamant
    Gottlieb, Alice B.
    Asahina, Akihiko
    Lebwohl, Mark
    McInnes, Iain B.
    Warren, Richard
    Boehncke, Wolf-Henning
    Ink, Barbara
    Bajracharya, Rajan
    Coarse, Jason
    Merola, Joseph F.
    ACTA DERMATO-VENEREOLOGICA, 2024, 104
  • [26] Bimekizumab Long-Term Safety and Efficacy in Patients with Ankylosing Spondylitis: Interim Results After 3 Years of Treatment in an Ongoing Phase 2b Study
    Gensler, Lianne
    Deodhar, Atul
    van der Heijde, Desiree
    Poddubnyy, Denis
    Kivitz, Alan
    Dougados, Maxime
    de Peyrecave, Natasha
    Oortgiesen, Marga
    Vaux, Thomas
    Fleurinck, Carmen
    Baraliakos, Xenofon
    ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 1015 - 1019
  • [27] LONG-TERM SAFETYOF IXEKIZUMAB IN ADULT PATIENTS WITH PSORIASIS, PSORIATIC ARTHRITIS, AND AXIAL SPONDYLOARTHRITIS
    Deodhar, Atul
    Blauvelt, Andrew
    Schwartzman, Sergio
    Salvarani, Carlo
    Feely, Meghan
    Kronbergs, Andris
    Rahman, Proton
    Marzo-Ortega, Helena
    de Lima Tostes, Camila
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2023, 29 : S99 - S99
  • [28] Resolution of enthesitis and peripheral arthritis with bimekizumab in patients with axial spondyloarthritis: Week 52 results from the BE MOBILE 1 and BE MOBILE 2 Phase 3 studies
    Ramiro, S.
    Poddubnyy, D.
    Mease, P. J.
    Lopez-Medina, C.
    Fleurinck, C.
    Kim, M.
    Massow, U.
    Taieb, V
    Vyncke, L.
    Wenzel, Kragstrup T.
    McGonagle, D. G.
    SWISS MEDICAL WEEKLY, 2023, 153 : 23S - 24S
  • [29] Long-Term Safety and Tolerability Of Apremilast, An Oral Phosphodiesterase 4 Inhibitor, In Patients With Psoriatic Arthritis: Pooled Safety Analysis Of Three Phase 3, Randomized, Controlled Trials
    Mease, Philip J.
    Kavanaugh, Arthur
    Gladman, Dafna D.
    Adebajo, Adewale O.
    Gomez-Reino, Juan J.
    Wollenhaupt, Juergen
    Cutolo, Maurizio
    Schett, Georg
    Lespessailles, Eric
    Shah, Kamal
    Hu, ChiaChi
    Stevens, Randall M.
    Edwards, Christopher J.
    Birbara, Charles A.
    ARTHRITIS AND RHEUMATISM, 2013, 65 : S131 - S132
  • [30] LONG-TERM SAFETY AND TOLERABILITY OF APREMILAST, AN ORAL PHOSPHODIESTERASE 4 INHIBITOR, IN PATIENTS WITH PSORIATIC ARTHRITIS: POOLED SAFETY ANALYSIS OF THREE PHASE 3, RANDOMIZED, CONTROLLED TRIALS
    Mease, P. J.
    Kavanaugh, A.
    Gladman, D.
    Adebajo, A. O.
    Gomez-Reino, J. J.
    Wollenhaupt, J.
    Cutolo, M.
    Schett, G.
    Lespessailles, E.
    Shah, K.
    Hu, C.
    Stevens, R.
    Edwards, C.
    Birbara, C.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 742 - 743
12345